Avista Pharma doubles API capacity at Longmont production facility

Monday November 13, 2017 0 comments Tags: Longmont, Avista Pharma Solutions, Ken Domagalski

LONGMONT-- Avista Pharma Solutions, Inc. announced it has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont site.avista-pharma-logo

During the expansion, Avista Pharma said the site’s three existing GMP drug substance manufacturing suites were upgraded and a fourth GMP suite was added. The facility’s non-GMP capacity was also doubled with the addition of two large-scale development suites, the company said.

Among the new equipment installations were four walk-in hoods, three 50-gallon glass-lined reactors, three Hastelloy agitated filter dryers, and various small-scale reactors and mixing vessels.

The new, state-of-the-art equipment will provide additional scale and enable processing of complex and potent categories of chemical compounds, the company said.

Safety and containment controls were also upgraded during the expansion, giving Avista Pharma the ability to manufacture materials rated up to occupational exposure bands of 3A and 3B by SafeBridge®.

“Our investments in suite upgrades and capacity expansion in Longmont have transformed the site into a world-class API manufacturing facility,” said Ken Domagalski, Avista’s general manager of the Longmont facility.

“Our team of experienced scientists prides itself in finding the most efficient path to success for our clients, further demonstrating our facility as a CMC center of excellence.”

The API facility expansion is one of several major investments at the Longmont site during 2017.

Avista Pharma said it is also in the process of expanding its drug product manufacturing capacity and analytical capacity, as well as adding walk-in stability storage chambers into the additional 20,000-square-foot expansion announced last year.